MA29879B1 - Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih - Google Patents

Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih

Info

Publication number
MA29879B1
MA29879B1 MA30862A MA30862A MA29879B1 MA 29879 B1 MA29879 B1 MA 29879B1 MA 30862 A MA30862 A MA 30862A MA 30862 A MA30862 A MA 30862A MA 29879 B1 MA29879 B1 MA 29879B1
Authority
MA
Morocco
Prior art keywords
optionally substituted
lower alkyl
substituted lower
heterocycle
hydrogen
Prior art date
Application number
MA30862A
Other languages
English (en)
Inventor
Hiroshi Yoshida
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37967785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29879(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MA29879B1 publication Critical patent/MA29879B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Consiste à proposer un nouveau composé ayant une activité anti-virale, particulièrement une activité inhibitrice de l'intégrase du VIH, et une composition pharmaceutique, particulièrement un agent anti-VIH. (dans laquelle R1 est un hydrogène ou un alkyle inférieur ; X est un alkylène inférieur, etc. : R2 est un aryle facultativement substitué ; R3 est un hydrogène, un halogène, un hydroxy, un alkyle inférieur facultativement substitué, etc. : R4 est un hydrogène, un alkyle inférieur facultativement substitué, un cycloalkyle facultativement substitué, un cycloalkyle alkyle inférieur facultativement substitué, un aryle facultativement substitué, un aryle alkyle inférieur facultativement substitué, un groupement hétérocyclique facultativement substitué, un hétérocycle alkyle inférieur facultativement substitué, etc. : Une ligne de tirets indique la présence ou l'absence d'une liaison ; B1 et B2 sont tels que l'un quelconque d'entre eux est un CR20R21, et l'autre est un NR22 et, dans ce cas, il n'y a pas de ligne de tirets. Quand B2 est un NR22, R4 et R22 peuvent être pris ensemble pour former un hétérocycle facultativement substitué ; Quand B2 est CHR21, R4 et R21 peuvent être pris ensemble pour former un hétérocycle facultativement substitué. À titre d'alternative, B1 et B2 sont indépendamment un C, un CR23 ou un N et, dans ce cas, B1 et B2 peuvent être pris ensemble pour former un hétérocycle. R20, R21, R22 et R23 sont indépendamment un hydrogène, un alkyle inférieur facultativement substitué, un cycloalkyle facultativement substitué, un cycloalkyle alkyle inférieur facultativement substitué, etc.)
MA30862A 2005-10-27 2008-04-23 Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih MA29879B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005312076 2005-10-27
JP2006223875 2006-08-21

Publications (1)

Publication Number Publication Date
MA29879B1 true MA29879B1 (fr) 2008-10-03

Family

ID=37967785

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30862A MA29879B1 (fr) 2005-10-27 2008-04-23 Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih

Country Status (15)

Country Link
US (2) US8188271B2 (fr)
EP (1) EP1950212B1 (fr)
JP (1) JP5131689B2 (fr)
KR (1) KR20080064182A (fr)
AU (1) AU2006307101A1 (fr)
BR (1) BRPI0617842A2 (fr)
CA (1) CA2626956A1 (fr)
EA (1) EA200801144A1 (fr)
ES (1) ES2569357T3 (fr)
IL (1) IL190879A0 (fr)
MA (1) MA29879B1 (fr)
MX (1) MX2008005137A (fr)
NO (1) NO20081892L (fr)
TW (1) TW200800988A (fr)
WO (1) WO2007049675A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116764A1 (fr) 2005-04-28 2006-11-02 Smithkline Beecham Corporation Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
CA2626956A1 (fr) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih
US7482345B2 (en) * 2005-12-05 2009-01-27 Meng-Hsin Chen P38 kinase inhibiting agents
DK2220076T5 (da) 2007-11-15 2012-09-17 Gilead Sciences Inc Inhibitorer af replikationen af humant immundefektvirus
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EP2320909B8 (fr) * 2008-07-25 2016-03-30 VIIV Healthcare Company Composés chimiques
ES2964383T3 (es) 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PT2444400T (pt) 2009-06-15 2018-06-06 Shionogi & Co Derivado de carbamoilpiridona policíclico substituído
EP2488521B1 (fr) * 2009-10-13 2013-12-18 Elanco Animal Health Ireland Limited Inhibiteurs de l'intégrase macrocyclique
WO2011105590A1 (fr) * 2010-02-26 2011-09-01 日本たばこ産業株式会社 Dérivé de 1,3,4,8-tétrahydro-2h-pyrido[1,2-a]pyrazine et son utilisation comme inhibiteur d'intégrase de vih
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
SI2620436T1 (en) 2010-09-24 2018-08-31 Shionogi & Co., Ltd. A prodrug substituted polycyclic carbamoyl pyridone derivative
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
PE20221914A1 (es) 2011-12-28 2022-12-23 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
EP2797597B1 (fr) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
WO2014099586A1 (fr) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
US20140221380A1 (en) * 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP3008044B1 (fr) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
NO2865735T3 (fr) 2013-07-12 2018-07-21
CA2916993C (fr) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Composes polycycliques-carbomoylpyridone et leur utilisation pharmaceutique
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
AU2015214182B2 (en) 2014-02-07 2020-04-30 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3196201B1 (fr) * 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Dérivé de pyridone polycyclique possédant une activité inhibitrice d'intégrase
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2984130C (fr) 2015-04-28 2021-07-20 Shionogi & Co., Ltd. Derive de pyridone polycyclique substitue et promedicaments de celui-ci
HRP20230215T1 (hr) 2015-04-28 2023-04-14 Shionogi & Co., Ltd. Supstituirani policiklički derivati piridona i njihov predlijek
WO2016187788A1 (fr) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CN110494141A (zh) 2016-08-10 2019-11-22 盐野义制药株式会社 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
JP2020500866A (ja) * 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
WO2019160783A1 (fr) * 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2019230857A1 (fr) * 2018-05-31 2019-12-05 塩野義製薬株式会社 Dérivé de pyridone polycyclique
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
CR20230571A (es) * 2018-05-31 2024-01-22 Shionogi & Co DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644)
EP3815689A4 (fr) * 2018-06-27 2022-04-20 National University Corporation Hokkaido University Inhibiteur de la croissance d'arénavirus comprenant un dérivé de carbamoylpyridone polycyclique
CN112996789A (zh) * 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
WO2020072377A1 (fr) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose
EP4122537A1 (fr) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Composés tricycliques pontés de carbamoylpyridone et leur utilisation pharmaceutique
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
JPWO2021107065A1 (fr) * 2019-11-28 2021-06-03
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
JP7361013B2 (ja) * 2019-11-28 2023-10-13 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体を含有する医薬組成物
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
WO2022159387A1 (fr) 2021-01-19 2022-07-28 Gilead Sciences, Inc. Composés de pyridotriazine substitués et leurs utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
CZ20031028A3 (cs) * 2000-10-12 2003-08-13 Merck & Co., Inc. Aza- a polyazanaftalenylkarboxamidy
CN101513402B (zh) 2001-08-10 2012-03-21 盐野义制药株式会社 抗病毒药
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7300364B2 (en) 2004-02-06 2007-11-27 Acushnet Company Multi-layer golf ball having velocity gradient from faster center to slower cover
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2045242A1 (fr) 2002-08-13 2009-04-08 Shionogi&Co., Ltd. Composants hétérocycliques disposant d'une activité inhibitoire contre l'intégrase du HIV
AU2003267098B2 (en) 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1578748B1 (fr) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines et composes connexes convenant comme inhibiteurs de l'integrase du vih
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2005087766A1 (fr) * 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Inhibiteurs de l'intégrase du vih
CA2634499A1 (fr) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones et procedes d'inhibition de l'integrase du vih
EP1852434B1 (fr) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase
WO2006116764A1 (fr) * 2005-04-28 2006-11-02 Smithkline Beecham Corporation Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
CA2626956A1 (fr) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih

Also Published As

Publication number Publication date
JPWO2007049675A1 (ja) 2009-04-30
US20120208998A1 (en) 2012-08-16
WO2007049675A1 (fr) 2007-05-03
CA2626956A1 (fr) 2007-05-03
EP1950212A1 (fr) 2008-07-30
EA200801144A1 (ru) 2008-10-30
ES2569357T3 (es) 2016-05-10
NO20081892L (no) 2008-06-23
MX2008005137A (es) 2008-09-29
BRPI0617842A2 (pt) 2011-08-09
EP1950212A4 (fr) 2010-08-04
US20090143356A1 (en) 2009-06-04
AU2006307101A1 (en) 2007-05-03
TW200800988A (en) 2008-01-01
KR20080064182A (ko) 2008-07-08
JP5131689B2 (ja) 2013-01-30
EP1950212B1 (fr) 2016-02-24
US8188271B2 (en) 2012-05-29
IL190879A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
MA29879B1 (fr) Derive de carbamoylpyridone polycyclique ayant une activite d'inhibition sur l'integrase du vih
MA26952A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques.
Montoya et al. Antifungal phenothiazines: optimization, characterization of mechanism, and modulation of neuroreceptor activity
Ravichandran et al. Design, Synthesis, and Evaluation of Thiazolidinone Derivatives as Antimicrobial and Anti‐viral Agents
MA28973B1 (fr) Compose heterocyclique fusionne
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
Taha et al. Synthesis and evaluation of unsymmetrical heterocyclic thioureas as potent β-glucuronidase inhibitors
TR199701194T1 (xx) Aspartil proteaz�n oksijenlenmi� heterosikl i�eren s�lfonamit inhibit�rleri.
ATE288681T1 (de) Fungizide verbindungen
NO20023688L (no) Integrinekspresjonsinhibitorer
EA200400480A1 (ru) N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
CA2217737A1 (fr) Sulfamides contenant tetrahydrofurane (thf) et agissant comme inhibiteurs de la protease aspartyle
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
KR950017949A (ko) 벤조티오펜 화합물과 수용성 사이클로덱스트린의 수용성 내포착물, 및 그의 약학제제 및 제조 방법
DK1454903T3 (da) Thiadiazolinderivater til behandling af cancer
KR910004191A (ko) 신질환치료제
KR970032863A (ko) 활성산소-유리기 소거제
BR0308588A (pt) Inibidores de entrada de molécula pequena
MA27963A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BRPI0515451A (pt) quinolinas substituìdas com tiazolinona na posição 2
KR960704859A (ko) 벤조락탐 유도체
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
KR950703522A (ko) 벤젠설폰아미드유도체 및 그 용도